332 related articles for article (PubMed ID: 35879763)
1. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis.
Li M; Yi T; Fan F; Qiu L; Wang Z; Weng H; Ma W; Zhang Y; Huo Y
Cardiovasc Diabetol; 2022 Jul; 21(1):139. PubMed ID: 35879763
[TBL] [Abstract][Full Text] [Related]
2. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
3. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
5. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials.
Li M; Zhang J; Yang G; Zhang J; Han M; Zhang Y; Liu Y
Eur J Clin Pharmacol; 2023 Jun; 79(6):859-871. PubMed ID: 37097298
[TBL] [Abstract][Full Text] [Related]
7. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
[TBL] [Abstract][Full Text] [Related]
8. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
Tanashat M; Manasrah A; Abouzid M
Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
[TBL] [Abstract][Full Text] [Related]
11. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
Wei W; Liu J; Chen S; Xu X; Guo D; He Y; Huang Z; Wang B; Huang H; Li Q; Chen J; Chen H; Tan N; Liu Y
Front Endocrinol (Lausanne); 2022; 13():850836. PubMed ID: 35330914
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
13. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
15. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
16. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
[TBL] [Abstract][Full Text] [Related]
18. Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials.
Oriecuia C; Tomasoni D; Sala I; Bonfioli GB; Adamo M; Gussago C; Lombardi CM; Pagnesi M; Savarese G; Metra M; Specchia C
Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):147-157. PubMed ID: 37985675
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials.
Camilli M; Lombardi M; Chiabrando JG; Zito A; Del Buono MG; Vergallo R; Aspromonte N; Lombardo A; Montone RA; Niccoli G; Biondi-Zoccai G; Crea F; Minotti G
Am J Ther; 2021 Nov; 29(2):e199-e204. PubMed ID: 35389572
[TBL] [Abstract][Full Text] [Related]
20. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
